JP2019534003A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534003A5
JP2019534003A5 JP2019521455A JP2019521455A JP2019534003A5 JP 2019534003 A5 JP2019534003 A5 JP 2019534003A5 JP 2019521455 A JP2019521455 A JP 2019521455A JP 2019521455 A JP2019521455 A JP 2019521455A JP 2019534003 A5 JP2019534003 A5 JP 2019534003A5
Authority
JP
Japan
Prior art keywords
seq
adi
nos
antigen
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019521455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534003A (ja
JP7265984B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/057708 external-priority patent/WO2018075954A2/en
Publication of JP2019534003A publication Critical patent/JP2019534003A/ja
Publication of JP2019534003A5 publication Critical patent/JP2019534003A5/ja
Priority to JP2022066241A priority Critical patent/JP2022087247A/ja
Application granted granted Critical
Publication of JP7265984B2 publication Critical patent/JP7265984B2/ja
Priority to JP2023146398A priority patent/JP7616813B2/ja
Priority to JP2023146397A priority patent/JP2023158193A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019521455A 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法 Active JP7265984B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022066241A JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662411510P 2016-10-21 2016-10-21
US62/411,510 2016-10-21
PCT/US2017/057708 WO2018075954A2 (en) 2016-10-21 2017-10-20 Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022066241A Division JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Publications (3)

Publication Number Publication Date
JP2019534003A JP2019534003A (ja) 2019-11-28
JP2019534003A5 true JP2019534003A5 (enExample) 2020-11-26
JP7265984B2 JP7265984B2 (ja) 2023-04-27

Family

ID=60263072

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019521455A Active JP7265984B2 (ja) 2016-10-21 2017-10-20 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022066241A Withdrawn JP2022087247A (ja) 2016-10-21 2022-04-13 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146397A Withdrawn JP2023158193A (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
JP2023146398A Active JP7616813B2 (ja) 2016-10-21 2023-09-08 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法

Country Status (4)

Country Link
US (3) US11479600B2 (enExample)
EP (1) EP3529272A2 (enExample)
JP (4) JP7265984B2 (enExample)
WO (1) WO2018075954A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3974447A3 (en) 2016-10-21 2022-09-07 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP4562034A1 (en) * 2022-07-27 2025-06-04 Humabs Biomed SA Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
WO2024259075A1 (en) * 2023-06-14 2024-12-19 Tether Therapeutics, Inc. Polymer formulations for delivery of polynucleotides
WO2025104604A1 (en) * 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5762905A (en) 1992-09-16 1998-06-09 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
EP0724602A4 (en) 1993-07-30 1998-12-23 Oravax Inc MONOCLONAL IgA ANTIBODIES AGAINST RESPIRATORY SYNCYTIAL VIRUS
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
US20020141990A1 (en) 1996-11-01 2002-10-03 Smithkline Beecham Corporation Anti-RSV human monoclonal antibodies
CN1188111C (zh) 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
US6656467B2 (en) 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2341074A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
AU2001241918A1 (en) 2000-03-02 2001-09-12 Med Immune, Inc. Methods of enhancing activity of vaccines and vaccine compositions
CA2407292A1 (en) 2000-05-03 2001-11-08 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2010081856A1 (en) 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
EP1617805A4 (en) 2003-04-11 2012-07-04 Medimmune Llc METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
AU2006223002A1 (en) 2005-03-14 2006-09-21 Medimmune, Llc Macromolecules comprising a thioether cross-link
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN101679513A (zh) 2007-03-06 2010-03-24 西福根有限公司 用于治疗呼吸道合胞病毒感染的重组抗体
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN101821289A (zh) 2007-09-07 2010-09-01 西福根有限公司 重组制造抗rsv抗体的方法
WO2009042589A1 (en) 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
KR100938998B1 (ko) 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
JP5575377B2 (ja) 2008-07-18 2014-08-20 シスメックス株式会社 抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
MX340541B (es) 2009-06-05 2016-07-13 Alblynx Nv Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
DK2950886T3 (da) * 2013-02-01 2020-03-23 Medimmune Llc Respiratorisk syncytialvirus-f-protein-epitoper
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
HK1221908A1 (zh) 2013-04-29 2017-06-16 Adimab, Llc 多特异(polyspecificity)试剂,其制备方法和用途
SI3094353T1 (sl) 2014-01-15 2020-07-31 Medimmune, Llc RSY-specifična protitelesa in njihovi funkcionalni deli
SG11201703403TA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
EP3974447A3 (en) 2016-10-21 2022-09-07 Adimab, LLC Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Similar Documents

Publication Publication Date Title
JP2019534003A5 (enExample)
JP2020518599A5 (enExample)
JP5808536B2 (ja) 抗rsvgタンパク質抗体
JP5734988B2 (ja) Rsv特異的結合分子
JP2018503361A5 (enExample)
JP2010528601A5 (enExample)
JP2018108086A5 (enExample)
JP2018506966A5 (enExample)
JP2012504955A5 (enExample)
JP2018184417A5 (enExample)
JP2016512554A5 (enExample)
JP2011528902A5 (enExample)
JP2015522252A5 (enExample)
JP2018535650A5 (enExample)
FI3484915T3 (fi) Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä
JP2016503413A5 (enExample)
JP2010516229A5 (enExample)
JP2014524748A5 (enExample)
JP2022065140A (ja) 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
RU2015136392A (ru) Композиции и способы, основанные на нейтрализующих антителах, доставляемых интраназально, для улучшенной терапевтической эффективности
JP2020521797A5 (enExample)
JP2019531293A5 (enExample)
JP2018533569A5 (enExample)
Diethelm-Varela et al. New developments and challenges in antibody-based therapies for the respiratory syncytial virus
Bergeron et al. Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine